

1 **CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND**  
2 **MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH**  
3 **ADVANCED SOLID CANCERS**

4  
5 Tyler Shugg, PharmD, PhD<sup>1\*</sup>; Reynold C. Ly, PhD<sup>1\*</sup>; Elizabeth J. Rowe, PhD<sup>1</sup>; Santosh Philips,  
6 PhD<sup>1</sup>; Mustafa A. Hyder, MD<sup>1</sup>; Milan Radovich, PhD<sup>2</sup>; Marc B. Rosenman, MD<sup>3</sup>; Victoria M.  
7 Pratt, PhD<sup>4</sup>; John T. Callaghan, MD, PhD<sup>1,5</sup>; Zeruesenay Desta, PhD<sup>1</sup>; Bryan P. Schneider, MD<sup>2</sup>;  
8 Todd C. Skaar, PhD<sup>1</sup>

9  
10 <sup>1</sup>Division of Clinical Pharmacology, Department of Medicine, Indiana University School of  
11 Medicine, Indianapolis, IN; <sup>2</sup>Division of Hematology/Oncology, Department of Medicine,  
12 Indiana University School of Medicine, Indianapolis, IN; <sup>3</sup>Ann & Robert H. Lurie Children's  
13 Hospital of Chicago and Institute of Public Health, Feinberg School of Medicine, Northwestern  
14 University, Chicago, IL; <sup>4</sup>Department of Medical and Molecular Genetics, Indiana University  
15 School of Medicine, Indianapolis, IN; <sup>5</sup>Department of Pharmacology and Toxicology, Indiana  
16 University School of Medicine, Indianapolis, IN

17 \*These authors contributed equally to this work

18  
19 **Acknowledgement of Research Support:**

20 This research was supported by NIGMS R35GM131812 (awarded to TCS) and funds from the  
21 Indiana University Grand Challenge to support the institutional Precision Health Initiative  
22 (provides salary and research support to TS, RCL, EJR, SP, MR, BPS, and TCS).

23  
24 **Corresponding Author:**

25 Todd C. Skaar, PhD  
26 Professor of Medicine  
27 Division of Clinical Pharmacology, Department of Medicine  
28 Indiana University School of Medicine  
29 Research II, E419  
30 950 W Walnut St.  
31 Indianapolis, IN 46202  
32 Email: [tskaar@iu.edu](mailto:tskaar@iu.edu)  
33 Phone: 317-274-2821

34  
35 **Running Head:** Opportunities for precision medicine in advanced cancer patients

36  
37 **Where Presented:** Presented as a virtual poster at the 2021 annual meeting of the American  
38 Society for Clinical Pharmacology and Therapeutics

47 **ABSTRACT**

48 **PURPOSE:** Precision medicine approaches, including germline pharmacogenetics (PGx) and  
49 management of drug-drug interactions (DDIs), are likely to benefit advanced cancer patients who  
50 are frequently prescribed multiple concomitant medications to treat cancer and associated  
51 conditions. Our objective was to assess the potential opportunities for PGx and DDI management  
52 within a cohort of adults with advanced cancer.

53 **PATIENTS AND METHODS:** Medication data were collected from the electronic health  
54 records (EHRs) for 481 subjects since their first cancer diagnosis. All subjects were genotyped  
55 for variants with clinically actionable recommendations in Clinical Pharmacogenetics  
56 Implementation Consortium (CPIC) guidelines for 13 pharmacogenes. DDIs were defined as  
57 concomitant prescription of strong inhibitors or inducers with sensitive substrates of the same  
58 drug-metabolizing enzyme and were assessed for six major cytochrome P450 (CYP) enzymes.

59 **RESULTS:** Approximately 60% of subjects were prescribed at least one medication with CPIC  
60 recommendations, and ~14% of subjects had an instance for actionable PGx, defined as  
61 prescription of a drug in a subject with an actionable genotype. The overall subject-level  
62 prevalence of DDIs and serious DDIs were 50.3% and 34.8%, respectively. Serious DDIs were  
63 most common for CYP3A, CYP2D6, and CYP2C19, occurring in 24.9%, 16.8%, and 11.7% of  
64 subjects, respectively. When assessing PGx and DDIs together, ~40% of subjects had at least one  
65 opportunity for a precision medicine-based intervention and ~98% of subjects had an actionable  
66 phenotype for at least one CYP enzyme.

67 **CONCLUSION:** Our findings demonstrate numerous clinical opportunities for germline PGx  
68 and DDI management in adults with advanced cancer.

69  
70

## 71 INTRODUCTION

72 Pharmacogenetics (PGx) and management of drug-drug interactions (DDIs) are two  
73 aspects of precision medicine that have the potential to optimize medication therapy in oncology  
74 and other therapeutic disciplines. PGx-guided approaches have been shown to enhance drug  
75 efficacy and safety, including results from prospective clinical trials that have demonstrated the  
76 potential for PGx to improve drug safety.<sup>1-3</sup> Accordingly, the U.S. Food and Drug  
77 Administration (FDA) currently includes PGx information within the labels for nearly 300  
78 medications.<sup>4</sup> Moreover, clinical practice guidelines that include PGx-guided recommendations  
79 have been published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and  
80 prominent discipline-specific professional organizations (e.g., the National Comprehensive  
81 Cancer Network) for over 100 medications.<sup>5,6</sup> Similarly, DDIs are known to contribute to  
82 adverse drug events,<sup>7,8</sup> and strategies to manage DDIs have been shown to improve patient  
83 outcomes.<sup>9</sup> Given their important clinical implications, DDIs constitute a major consideration  
84 both during drug development and in clinical medicine, and recommendations to manage DDIs  
85 are therefore included both in FDA drug development guidance to industry<sup>10</sup> and in numerous  
86 clinical practice guidelines.<sup>11,12</sup>

87 The clinical utility of precision medicine is expected to be especially high for patients  
88 with advanced cancer given that drug therapy is commonly used not only to treat cancer, but also  
89 to manage both cancer treatment-related adverse events (e.g., nausea and vomiting) and  
90 comorbid conditions associated with cancer (e.g., psychiatric conditions and pain syndromes).  
91 As a result, polypharmacy, typically defined as the concomitant use of 5 or more drugs, is  
92 exceedingly common in advanced cancer patients.<sup>13</sup> Polypharmacy carries an increased risk for  
93 DDIs,<sup>14</sup> and, predictably, multiple investigations<sup>14</sup> have identified serious DDIs in advanced  
94 cancer that impact patient outcomes.<sup>15</sup> PGx-guided approaches also offer the ability to optimize

95 therapy for numerous anticancer medications based on somatic and germline genetic biomarkers.  
96 While molecular tumor boards have effectively harnessed somatic genome-guided treatment  
97 approaches to improve patient outcomes,<sup>16</sup> germline PGx biomarkers can enhance medication  
98 safety with agents such as fluoropyrimidine and thiopurine chemotherapies.<sup>17,18</sup> Additionally,  
99 PGx-guided approaches have been shown to enhance both efficacy and safety of selective  
100 serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and opioid analgesics  
101 that are often prescribed for comorbid conditions prevalent in cancer.<sup>19-21</sup> Given these abundant  
102 PGx opportunities in cancer patients, it has been suggested that preemptive testing for PGx  
103 variants at first cancer diagnosis may be an effective clinical strategy to optimize patient  
104 outcomes.<sup>22</sup> Furthermore, recent advancements in bioinformatics technology have enhanced the  
105 feasibility of PGx approaches in cancer through the creation of methods to extract PGx  
106 information from existing germline sequencing data generated during the clinical workflow of  
107 molecular tumor boards.<sup>23,24</sup>

108         Although past studies have characterized opportunities for DDI management and PGx-  
109 guided approaches in patients with advanced cancer, we are not aware of any work that has  
110 simultaneously investigated both approaches to provide a comprehensive assessment of the  
111 potential for precision medicine. Therefore, the objective of this study was to determine  
112 composite opportunities for precision medicine, incorporating both PGx-guided and DDI  
113 management strategies, within a cohort of adults with advanced solid cancers. By analyzing the  
114 potential for PGx-guided interventions since each subject's respective date of first cancer  
115 diagnosis, we also directly investigate the potential clinical utility of preemptively obtaining PGx  
116 information when patients are first diagnosed with cancer.

117

## 118 **METHODS**

## 119 **Subject Enrollment and Eligibility**

120           This study was a retrospective electronic health record (EHR) review and prospective  
121 genotyping of eligible patients with solid cancers at Indiana University Health in Indianapolis,  
122 Indiana, USA. Subjects were eligible to participate in the study if they 1) had been seen in the  
123 Indiana University Health Precision Genomics clinic and enrolled in the accompanying Indiana  
124 University Total Cancer Care Protocol (part of the larger Oncology Research Information  
125 Exchange Network-wide Total Cancer Care initiative [<https://www.oriencancer.org/>]) and 2)  
126 agreed to submit a blood sample for genotyping. Subjects were enrolled into the study at clinic  
127 visits from February 2015 to February 2018. This research protocol, as well as the parent Total  
128 Cancer Care Protocol, were approved by Indiana University's Institutional Review Board. All  
129 subjects provided written informed consent.

130

## 131 **Study Design and Data Collection**

132           The purpose of this study was to investigate potential opportunities for precision  
133 medicine interventions, including PGx and management of DDIs, within a cohort of 481 adults  
134 seen at our institutional precision oncology clinic and associated solid tumor board.  
135 Demographic and clinical data, including medication prescriptions, were collected from the  
136 EHRs of all institutions participating in the Indiana Health Information Exchange, a statewide  
137 EHR data repository that includes 38 healthcare systems. Demographic data included age, sex,  
138 and race. Clinical data included first oncologic diagnosis and all inpatient and outpatient  
139 prescriptions. Genotyping for major pharmacogenes was performed at the College of American  
140 Pathologists-accredited Indiana University Pharmacogenomics Laboratory using a laboratory-  
141 developed assay based on the OpenArray<sup>®</sup> Platform (ThermoFisher; Waltham, MA). The genes

142 included on the genotyping platform, along with the number of variants tested for each gene,  
143 were as follows: *CYP2B6* (2), *CYP2C19* (6), *CYP2C9* (6), *CYP2D6* (11, including copy number  
144 targeting exon 9), *CYP3A4* (2), *CYP3A5* (3), *CYP4F2* (1), *DPYD* (2), *G6PD* (2), *IFNL3* (1),  
145 *SLCO1B1* (2), *TPMT* (2), and *VKORC1* (1). Detailed genotyping methods are provided in the  
146 **Supplemental Methods**, and a complete list of tested variants is shown in **Table S1**.

147

### 148 **Medication Inclusion into Precision Medicine Analyses**

149 The PGx analysis included 46 medications with published guidelines as of 09/25/20 by  
150 CPIC (full list available in **Table S2** and online).<sup>5</sup> Drugs were considered for inclusion in the  
151 DDI analysis if they were listed as substrates, inhibitors, or inducers of *CYP2B6*, *CYP2C19*,  
152 *CYP2C8*, *CYP2C9*, *CYP2D6*, or *CYP3A* within 1) the “Clinical substrates,” “Clinical  
153 inhibitors,” or “Clinical inducers” tables of the current version (as of 09/25/20) of the U.S. Food  
154 and Drug Administration’s “Drug Development and Drug Interactions: Table of Substrates,  
155 Inhibitors and Inducers”<sup>25</sup> or 2) the Indiana University School of Medicine’s Drug Interactions  
156 Flockhart Table™.<sup>26</sup> Medications contained in these resources were reviewed for inclusion into  
157 DDI analyses based on the expertise of the study team. The final list of included substrates,  
158 inhibitors, and inducers are displayed in **Table S2**. Medications included in the DDI analysis  
159 between tyrosine kinase inhibitors (TKIs) and acid reducers are also listed in **Table S2**. Within  
160 our analyses, acid reducers included antacids, histamine-2 receptor antagonists (H2RAs), proton  
161 pump inhibitors (PPIs), and sucralfate.

162

### 163 **PGx Analyses**

164           Within our analyses, PGx recommendations for drug-gene pairs were classified by  
165 genotype-predicted phenotype (e.g., metabolizer status) based on annotations from the  
166 Pharmacogenomics Knowledge Base (PharmGKB). Phenotypes were considered actionable if  
167 CPIC guidelines recommended a clinical action to manage the drug-gene interaction (see **File S1**  
168 for actionability determinations). Specific clinical actions included adjustment of initial or  
169 maintenance dosing, selection of alternative therapy, or performing additional tests to determine  
170 enzyme activity.

171           Using these determinations, we considered genotype-predicted phenotypes as actionable  
172 within our phenotype distribution (**Table 2**) if CPIC guidelines for one or more drug-gene pairs  
173 recommended clinical action based on the specified phenotype. For our analyses characterizing  
174 the prevalence of actionable PGx opportunities, we only included instances where a medication  
175 was prescribed to a subject with a CPIC-defined actionable genotype-predicted phenotype for  
176 that same medication (e.g., prescription of clopidogrel in a CYP2C19 poor metabolizer).

## 178 **DDI Analyses**

179           DDIs involving CYP enzymes were defined as concomitant prescription of an inhibitor or  
180 inducer with a sensitive substrate of the same drug-metabolizing enzyme. To account for  
181 temporal delays in CYP induction and de-induction following the onset and offset of CYP  
182 inducers, the window for DDIs with co-administered CYP substrates was defined as starting 7  
183 days after initiation of inducer therapy and lasting 7 days after termination of inducer therapy.  
184 DDIs involving CYP enzymes were analyzed for CYP2B6, CYP2C19, CYP2C8, CYP2C9,  
185 CYP2D6, and CYP3A for each patient from their date of first cancer diagnosis until the last date

186 of data collection (04/20/20). DDIs were also assessed for concomitant prescription of drug-drug  
187 pairs that included TKIs and medications known to reduce gastrointestinal acidity.

188       Extracted medication data contained the date, time, and location (i.e., whether  
189 administered in a medical setting, including outpatient clinics, or whether dispensed from a  
190 pharmacy) for each prescription. The days supply for each prescription was conservatively  
191 estimated using the following assumptions. For prescriptions administered in a medical setting,  
192 the days supply was assumed to be one. For prescriptions dispensed from a pharmacy, the days  
193 supply was assumed based on the shortest days supply for indications for which the drug is  
194 typically prescribed (see **Table S3** for a complete list of assumed durations for all prescriptions  
195 dispensed from a pharmacy). An exception to this method was made for prescriptions dispensed  
196 from a pharmacy that were 1) dispensed for at least three consecutive regular intervals (e.g.,  
197 every 30 days, every 90 days) and 2) written for medications that are commonly used as  
198 maintenance therapy for chronic medical conditions (e.g., antihypertensives). For these  
199 prescriptions, the patient was assumed to be taking the medication for the entire interval between  
200 consecutive prescriptions.

201       Instances of autoinhibition and autoinduction (i.e., a medication altering its own  
202 metabolism upon chronic administration) were not considered as DDIs in our analyses. In  
203 addition, DDIs involving common chemotherapy regimens (e.g., prednisone and docetaxel) were  
204 not included in our analyses. Instances of co-administration of multiple proton pump inhibitors  
205 were also not considered as DDIs.

206       We defined “serious DDIs” as DDI pairs with sensitive substrate drugs that have one or  
207 more of the following: 1) a narrow therapeutic index, 2) indications as cancer treatments, or 3) an  
208 association with significant adverse drug reactions (see bolded drugs in **Table S2**).



209

## 210 **Composite Precision Medicine Analyses**

211           The prevalence of CYP inhibitor-mediated phenoconversion was assessed for CYP2B6,  
212 CYP2C19, CYP2C9, CYP2D6, and CYP3A4. Within our analyses, we coded subjects as  
213 positive for CYP inhibitor-mediated phenoconversion if they were (1) genotype-predicted  
214 ultrarapid, rapid, normal, or intermediate metabolizers and (2) prescribed a relevant strong CYP  
215 inhibitor at any time after first cancer diagnosis.

216

## 217 **Statistical Analyses**

218           Data for the PGx and DDI analyses were analyzed using descriptive statistics (counts and  
219 percentages) using JMP Pro v.15.0.0.

220

## 221 **RESULTS**

### 222 **Subject Demographic, Clinical, and Medication Data**

223           Demographic and clinical characteristics of the 481 study subjects with advanced cancer  
224 included are shown in **Table 1**. Our cohort was a median of  $57 \pm 16.6$  (median  $\pm$  interquartile  
225 range [IQR]) years old, and most subjects were white (87.9%) and female (53.2%). The most  
226 common types of cancer at first diagnosis included breast (12.7%), pancreatic (10.8%), and  
227 colorectal (9.6%). The median duration of follow-up, defined as the time between the date of  
228 first cancer diagnosis and the date of last prescription, was  $2.9 \pm 4.9$  (median  $\pm$  IQR) years.

229           Extracted medication data contained  $\geq 1$  prescription for 469 out of 481 (97.5%) subjects.  
230 Filtering to include only prescriptions since each subject's respective date of first cancer  
231 diagnosis yielded 158,188 unique prescriptions that were assessed within our precision medicine

232 analyses (schematic of filtering results shown in **Figure S1**). Since first cancer diagnosis, our  
233 cohort had 1) a total of 7,074 unique prescriptions for medications contained within a CPIC  
234 guideline (herein called “PGx medications”) and 2) a total of 22,642 unique prescriptions for  
235 medications that were defined as inducers, inhibitors, or sensitive substrates of CYP2B6,  
236 CYP2C19, CYP2C8, CYP2C9, CYP2D6, and/or CYP3A, acid reducers, or TKIs (herein called  
237 “DDI medications”).

238

### 239 **PGx Analyses**

240 The distribution of genotype-predicted phenotypes within our cohort for all  
241 pharmacogenes is displayed in **Table 2**. When defining actionable phenotypes as those with  
242 clinically actionable recommendations within CPIC guidelines for at least one medication, the  
243 rates of actionable phenotypes were highest for CYP2C19 (59.5%) and VKORC1 (52.4%) and  
244 lowest for TPMT (7.3%), G6PD (1.5%), and DPYD (1.0%).

245 Of 469 analyzed subjects, 282 (60.1%) were prescribed at least one PGx medication.  
246 These included a total of 1,045 unique PGx medications (i.e., prescription of a unique PGx  
247 medication for a unique subject), with an average of  $2.2 \pm 2.4$  (mean  $\pm$  standard deviation) PGx  
248 medications/subject and a maximum of 12 PGx medications in one subject. When considering  
249 both prescribed medications and genotype-predicted phenotypes, we identified a total of 81  
250 unique opportunities for “actionable PGx,” defined as an instance where a PGx medication was  
251 prescribed to a subject with an actionable phenotype based on CPIC recommendations. Instances  
252 of actionable PGx occurred for 67 subjects (14.3%), with 56 subjects having instances of  
253 actionable PGx involving 1 medication, 8 subjects having actionable PGx involving 2  
254 medications, and 3 subjects having actionable PGx involving 3 medications.

255 The prevalence of instances of actionable PGx, when stratified by the drug-gene pairs  
256 involved, are shown in **Table 3**. For PGx medications prescribed in at least five subjects, the  
257 rates of actionable PGx were highest for warfarin (87.5%), amitriptyline (58.3%), and  
258 clopidogrel (42.9%). Conversely, capecitabine, 5-fluorouracil, sertraline, and celecoxib had no  
259 instances for actionable PGx. For warfarin, subjects had actionable PGx recommendations based  
260 on *CYP2C9*, *CYP4F2*, and *VKORC1* genotype-based phenotypes in 20.8%, 58.3%, and 50.0% of  
261 cases, respectively. For amitriptyline, subjects had actionable PGx recommendations based on  
262 *CYP2C19* and *CYP2D6* genotype-based phenotypes in 16.7% and 50.0% of cases, respectively.

263

#### 264 **DDI Analyses**

265 Of 469 analyzed subjects, the prevalence of  $\geq 1$  prescription for an inducer, inhibitor, or  
266 substrate of any CYP enzyme was 49.0%, 58.0%, and 64.0%, respectively. **Figure S2** displays  
267 the prevalence of subjects with prescriptions for inducers, inhibitors, and substrates across the six  
268 enzyme systems that were assessed. Prescriptions for CYP inducers were most common for  
269 *CYP2C19*, *CYP2C9*, and *CYP3A*, occurring in 49.0% of subjects. Prescriptions for inhibitors  
270 were most common for *CYP2D6* (occurring in 53.3% of subjects), *CYP2C9* (35.0%), *CYP3A*  
271 (33.9%), and *CYP2C19* (31.8%), while prescriptions for sensitive substrates were most common  
272 for *CYP3A*, *CYP2D6*, and *CYP2C19* (prescribed in 60.3%, 59.9%, and 48.2% of subjects,  
273 respectively).

274 When assessing concomitant prescription of both a relevant perpetrator (inducer or  
275 inhibitor) and victim (sensitive substrate) drug, 236 subjects (50.3%) had a DDI affecting at least  
276 one CYP enzyme system. Given the frequent use of corticosteroids to treat and manage  
277 treatment-related complications for many types of cancer,<sup>27</sup> we also performed DDI analyses

278 excluding corticosteroids, which are potent inducers of CYP2C19, CYP2C9, and CYP3A; 225  
279 subjects (48.0%) had a DDI affecting at least one major CYP enzyme when excluding  
280 corticosteroids. As shown in **Table 4**, the prevalence of DDIs in our cohort was highest for  
281 CYP2D6 (affecting 45.2% of subjects; average of 1.5 DDIs/subject), followed by CYP3A  
282 (29.9%; 0.8 DDIs/subject), CYP2C19 (23.9%; 0.5 DDIs/subject), CYP2C9 (11.7%; 0.2  
283 DDIs/subject), CYP2B6 (0.2%), and CYP2C8 (0%). When excluding corticosteroids, the  
284 prevalence of DDIs for CYP2C19, CYP2C9, and CYP3A was reduced to 10.2%, 7.0%, and  
285 20.3%, respectively (**Table 4**). The most common drug-drug pairs contained within observed  
286 DDIs, stratified by enzyme, are shown in **Table S4**. The subject-level prevalence for serious  
287 DDIs, which were classified by the substrates involved, was 34.8% for any CYP enzyme when  
288 including corticosteroids and 29.4% when excluding corticosteroids (**Table 4**). Serious DDIs  
289 were most common for CYP3A, occurring in 24.9% of subjects and including sensitive  
290 substrates like fentanyl, midazolam, and tramadol. In contrast, serious DDIs were less common  
291 for CYP2C19 (11.7% of subjects; sensitive substrates included escitalopram, sertraline, and  
292 citalopram), CYP2C9 (4.7% of subject; substrates included warfarin, dronabinol, and phenytoin),  
293 and CYP2D6 (16.8% of subject; substrates included tramadol, sertraline, and mirtazapine).  
294 When adjusting the prevalence of CYP enzyme-mediated DDIs based on subject genotype (i.e.,  
295 excluding DDIs involving inducer or inhibitor drugs in subjects who are genotype-predicted poor  
296 metabolizers), the subject-level prevalence is as follows: CYP2B6: 0.2%; CYP2C19: 23.9%;  
297 CYP2C8: 0%; CYP2C9: 11.7%; CYP2D6: 44.1%; and CYP3A: 29.6% (adjusted based on  
298 *CYP3A4* genotype).

299 TKIs have emerged as first-line treatment options for a variety of cancers. However,  
300 multiple investigations have described the potential for significant DDIs involving orally-

301 administered TKIs and acid reducing agents, including antacids, H2RAs, and PPIs, that reduce  
302 TKI bioavailability and impact treatment outcomes.<sup>28-31</sup> Accordingly, we characterized the  
303 prevalence of DDIs involving TKIs and acid reducers in our study population. Within our cohort,  
304 68 subjects (14.5%) were prescribed at least one TKI, with pazopanib (prescribed in 17 subjects),  
305 sunitinib (10), and crizotinib (9) being the most commonly prescribed. Of the 68 subjects  
306 prescribed a TKI, 33 (48.5%) had a concomitant prescription of at least one acid reducer. Within  
307 our population, the most common acid reducer classes involved in DDIs were PPIs (perpetrator  
308 drug in 34 DDIs), followed by H2RAs (10) and antacids (6).

309

### 310 **Composite Precision Medicine Analyses**

311 To assess the prevalence of composite opportunities for precision medicine interventions,  
312 we aggregated findings from our actionable PGx, serious CYP-mediated DDI, and acid reducer-  
313 TKI DDI analyses at the subject level. As shown in **Figure 1**, 186 subjects (39.7%) had at least  
314 one opportunity for a precision medicine intervention. 68 subjects (14.5%) had opportunities for  
315 more than one type of precision medicine intervention, with 9 of these subjects (1.9%) having  
316 opportunities for PGx and management of both CYP-mediated and acid reducer-TKI DDIs.

317 Finally, we assessed the prevalence of CYP inhibitor-mediated phenoconversion, the  
318 process by which co-administration of a strong inhibitor functionally converts those with any  
319 genotype to a poor metabolizer phenotype, for CYP2B6, CYP2C19, CYP2C9, CYP2D6, and  
320 CYP3A4. As shown in **Figure 2**, CYP inhibitor-mediated phenoconversion enhanced the  
321 number of subjects with actionable phenotypes for CYP2C19, CYP2C9, and CYP2D6, and  
322 CYP3A4, increasing the prevalence from 59.5% to 72.8%, 33.3% to 55.9%, 44.7% to 76.3%,  
323 and 8.9% to 38.9%, respectively. In contrast, CYP inhibitor-mediated phenoconversion only

324 slightly changed the number of actionable phenotypes for CYP2B6 (prevalence increased from  
325 48.4% to 49.1%) due to the low prevalence of prescription of CYP2B6 inhibitors within our  
326 cohort. When considering all five investigated CYPs together, nearly every subject in our cohort  
327 (98.3%) had an actionable phenotype (either genotype-predicted or from CYP inhibitor-mediated  
328 phenoconversion) for at least one CYP since their date of first cancer diagnosis. Also, 47  
329 subjects (9.8%) had genotype-predicted or phenoconverted actionable phenotypes for all five  
330 CYP enzymes.

331

## 332 **DISCUSSION**

333 In this investigation, we provide quantitative evidence to support the immense clinical  
334 opportunities for precision medicine approaches, including germline PGx and management of  
335 DDIs, in a cohort of patients with advanced cancer. Our findings indicate that ~14% of subjects  
336 had opportunities for actionable PGx (i.e., prescription of a PGx medication to a subject with a  
337 CPIC guideline-defined actionable genotype) and that ~35% and ~7% of subjects had a serious  
338 DDI involving major CYP enzymes and acid reducers co-prescribed with TKIs, respectively.  
339 When incorporating both PGx and DDIs, we found that ~40% of subjects had at least one  
340 opportunity for a precision medicine-based intervention and nearly all subjects (~98%) had an  
341 actionable phenotype (genetically-predicted or drug-induced) for  $\geq 1$  CYP enzyme. Based on our  
342 findings, implementation of precision medicine approaches at first cancer diagnosis is likely to  
343 provide clinical benefit to a significant proportion of patients. Although a limited number of  
344 other studies have addressed similar topics, our investigation has significant methodological  
345 advantages, including 1) a larger cohort (n=481), 2) a broader PGx analysis consisting of 13

346 CPIC-actionable pharmacogenes, and 3) utilization of a statewide data repository to enable more  
347 comprehensive collection of medication data.

348 Previous investigations have demonstrated the potential clinical impact of PGx  
349 approaches in patients with advanced cancer. Nichols, et al. catalogued medications in a cohort  
350 of 193 patients with advanced cancer, demonstrating that 65% of patients were taking at least  
351 one PGx medication (i.e., those with a CPIC guideline).<sup>32</sup> Using population estimates of allele  
352 frequencies, the authors predicted that 7.1% of patients in their cohort could benefit from at least  
353 one PGx intervention involving medications associated with nine major pharmacogenes:  
354 *CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-B, SLCO1B1, VKORC1*.  
355 Similarly, Hertz, et al. found that 2.6% of 115 adult and pediatric patients with cancer could have  
356 benefitted from a PGx intervention involving substrates of their analyzed drug-metabolizing  
357 enzymes, which included CYP2C19, DPYD, and TPMT.<sup>33</sup> An investigation by Kasi, et al. also  
358 predicted abundant opportunities for PGx interventions within their cohort of 155 patients with  
359 advanced cancer based on patient genotypes for major CYP450 enzymes, though they did not  
360 specifically collect and analyze medication data.<sup>34</sup> Many of our findings are similar to those  
361 reported in past investigations. For instance, our findings related to the prevalence of prescription  
362 of PGx medications are remarkably similar to results from Nichols, et al. when considering both  
363 prescription of any PGx medication (~60% in our analysis vs. 65% in their study) and  
364 prescription of specific PGx drugs such as ondansetron, capecitabine, and simvastatin.<sup>32</sup> Our  
365 findings related to the distribution of actionable phenotypes are also consistent with those from  
366 past investigations<sup>32,34</sup> as well as those predicted from large analyses of population allele  
367 frequencies.<sup>35</sup> In contrast, our finding for the prevalence of subjects with potential PGx  
368 interventions (14.3%) is higher than those reported by Nichols, et al. (7.1%) or Hertz, et al.

369 (2.6%).<sup>32,33</sup> These differences are likely attributable to the facts that we (1) investigated the  
370 potential for PGx interventions across a wider array of pharmacogenes and (2) that we utilized a  
371 statewide repository with prescription data from 38 health systems to enhance the richness of our  
372 collected medication data.

373 Multiple investigations have also characterized the clinical potential of DDI management  
374 strategies in adult patients with advanced cancer. A 2009 review by Riechelmann, et al.  
375 summarized the prevalence of potential DDIs from six studies, finding rates between 27% and  
376 72%.<sup>36</sup> The high variability they observed among studies is likely attributable to differences in  
377 employed methodologies (e.g., utilizing patient-verified medication lists versus all drugs listed in  
378 EHRs, focusing on all potential drug interactions versus only those involving cancer  
379 medications). More recently, investigations within the U.S. and abroad have characterized the  
380 prevalence of potential DDIs in cancer patients, finding rates of 40-78%.<sup>37-41</sup> Again, it appears  
381 that observed differences in potential DDI prevalence are due to methodological differences  
382 among the studies. For instance, we found that studies that included DDIs based on both  
383 pharmacokinetic (i.e., concomitant administration of an inhibitor or inducer of a drug-  
384 metabolizing enzyme along with a sensitive substrate of that enzyme) and pharmacodynamic  
385 (i.e., concomitant administration of two or more drugs with the same adverse event profile)  
386 mechanisms had higher rates of potential DDIs.<sup>38,39</sup> Similarly, studies that utilized medication  
387 lists taken from the EHR (rather than those verified by patients during medication reconciliation)  
388 had higher potential DDI prevalence.<sup>38,39</sup> The overall DDI prevalence of ~52% in our study falls  
389 in the middle of those reported by past investigations. In terms of methodology, extracting  
390 medication data from the EHR likely resulted in a higher DDI prevalence in our study relative to  
391 those that used patient-verified medications. We attempted to control for this by utilizing



392 prescription dates to only identify potential DDIs when there was temporal overlap in the  
393 prescription (and presumed coadministration) of perpetrator and victim drugs for the same CYP  
394 enzyme. Relative to other studies, our DDI prevalence was likely more conservative based on  
395 other elements in our methodology, including (1) that we excluded DDIs with pharmacodynamic  
396 mechanisms and (2) that we excluded DDIs involving drugs commonly co-administered as  
397 cancer treatment regimens (e.g., corticosteroids co-administered with docetaxel or vincristine).  
398 Our rationale for excluding these DDIs was that, in the case of pharmacodynamic DDIs, co-  
399 administration of drugs with similar adverse event profiles is often clinically indicated (e.g., dual  
400 antiplatelet therapy) and, in the case of DDIs within established cancer regimens, treating  
401 clinicians are familiar with these DDIs and have likely already determined a favorable risk-  
402 benefit ratio for the patient before prescribing. Therefore, based on these methodological  
403 elements, we believe our findings represent a conservative estimate of the prevalence of potential  
404 DDIs in advanced cancer patients involving major CYP enzymes. Additionally, our study  
405 expands on past investigations assessing potential DDI prevalence in a few significant ways.  
406 First, our results stratified DDI prevalence by the CYP enzymes involved, which could aid  
407 clinicians in selecting drugs with metabolic pathways less likely to be associated with DDIs.  
408 Next, we specifically investigated the prevalence of DDIs for acid reducing agents and TKIs,  
409 which has emerged as an important consideration in cancer precision medicine.<sup>42</sup> Finally, we  
410 performed both a composite subject-level analysis and CYP inhibitor-mediated phenoconversion  
411 analysis to elucidate the net prevalence of precision medicine opportunities in our study cohort  
412 that incorporate both PGx and DDI management approaches.

413 Our findings are impactful since they demonstrate the abundant clinical opportunities for  
414 precision medicine approaches to optimize medication therapy in patients with advanced cancer.

415 Specifically, we found that ~60% of subjects in our cohort were prescribed at least one PGx  
416 medication and that approximately 1 in 7 subjects had an opportunity for actionable PGx since  
417 their date of first cancer diagnosis. These findings directly support the clinical utility of PGx  
418 approaches in patients with cancer, including the suggestion of preemptive genotyping at first  
419 cancer diagnosis.<sup>22</sup> Advances in technology have also improved the feasibility of PGx  
420 approaches by reducing the costs associated with obtaining genetic information and enabling  
421 repurposing of genetic information obtained from molecular tumor boards.<sup>24</sup> In addition,  
422 economic analyses have demonstrated cost savings due to toxicity sparing for both *DPYD* and  
423 *TPMT* testing.<sup>43,44</sup> As a result, there is clinical momentum for standardized testing of PGx  
424 markers associated with fluoropyrimidine and thiopurine chemotherapies.<sup>45,46</sup> Our findings also  
425 corroborate those from other studies<sup>32,34</sup> in identifying significant opportunities for PGx to  
426 optimize supportive care therapies in patients with cancer, including SSRIs, TCAs, opioids, and  
427 commonly used antiemetics (e.g., ondansetron), based on CPIC guidelines.<sup>19-21,47</sup>

428       Related to the clinical opportunities for DDI management strategies, we found that  
429 slightly over half of our study subjects had a DDI affecting at least one major CYP enzyme since  
430 first cancer diagnosis. This finding is important given that DDIs have been associated with poor  
431 clinical outcomes and increased adverse drug events in cancer patients. For instance, CYP-  
432 mediated DDIs have been shown to increase the rates of adverse events attributable to both  
433 cancer therapies (e.g., increased paclitaxel-induced peripheral neuropathy during co-treatment  
434 with clopidogrel)<sup>48</sup> and concomitant medications (e.g., increased warfarin-induced bleeding  
435 during co-treatment with capecitabine)<sup>49</sup> in patients with cancer. Additionally, several studies  
436 have investigated the potential for DDIs between acid reducing agents and TKIs, demonstrating  
437 reduced progression-free and overall survival during concomitant therapy attributed to reduced

438 TKI systemic absorption.<sup>28-30</sup> Our findings support the potential for clinically significant DDIs  
439 between acid reducers and TKIs since we observed that these DDIs occurred in nearly half of  
440 subjects that were prescribed a TKI. However, it is possible that the providers told the patient to  
441 discontinue the acid reducers while taking the TKI's. Nonetheless, our findings support the  
442 clinical potential of DDI management strategies, which have been shown to improve outcomes in  
443 other populations,<sup>9</sup> in patients with advanced cancer. Finally, our work serves as one of the first  
444 investigations to assess the prevalence of potential drug-drug-gene interactions (DDGIs) (i.e.,  
445 CYP inhibitor-mediated phenoconversion) within a clinical cohort. While the strategies to  
446 manage DDGIs borrow from both PGx and DDI management approaches, consideration of  
447 DDGIs may provide critical information that modifies the risk of adverse drug events predicted  
448 from consideration of either approach in isolation.<sup>50</sup> As demonstrated by our composite study  
449 findings that ~40% of subjects had at least one opportunity for precision medicine intervention  
450 and ~98% of subjects had an actionable phenotype for  $\geq 1$  CYP enzymes, PGx information and  
451 concomitant drug lists should be used in tandem to most accurately inform approaches to  
452 optimize medication therapy. Given the complexities of DDGIs, including concepts like  
453 phenoconversion and interplay of multiple drug biotransformation pathways, expert guidance  
454 that includes perspectives from both clinical pharmacologists and clinicians is needed to inform  
455 actionable clinical management strategies.

456 We acknowledge several limitations of our study. First, our extracted medication data did  
457 not include a way to conclusively ascertain days supply in order to assess temporal overlap  
458 between perpetrator and victim drugs within our DDI analyses. To compensate for this  
459 limitation, we used conservative methods in our DDI analyses to estimate days supply for each  
460 prescription, as described in the methods. While this limitation may have influenced our findings

461 related to the prevalence of DDIs, it did not impact results from our PGx analyses. Our extracted  
462 medication data also did not consistently contain information about the medication dose. As a  
463 result, our analysis may have overestimated the prevalence of instances for actionable PGx with  
464 amitriptyline since current CPIC guidelines do not recommend clinical action at daily doses  
465 under 50 mg.<sup>19</sup> Also, our panel-based genotyping method only tested for relatively common  
466 functional variants in the assessed genes within our primary ethnic and racial populations,  
467 potentially excluding rare functional variants that alter drug response. While we do not expect  
468 that this approach significantly impacted our findings, it is important to note that utilizing panel-  
469 based genotyping (as opposed to a more complete approach like whole genome sequencing) may  
470 have caused us to underestimate the actual clinical opportunities for actionable PGx in our  
471 cohort. Additionally, advances in knowledge since study initiation limited our ability to assess  
472 variants with newly established relevance to pharmacotherapy (e.g., HapB3 in *DPYD*). Our  
473 genotyping panel also did not assess every pharmacogene included within a CPIC guideline.  
474 However, the pharmacogenes covered in our panel serve as the genetic basis for over 80% of the  
475 PGx recommendations contained within current CPIC guidelines.<sup>5</sup>

476 In conclusion, our work provides quantitative evidence of the vast clinical opportunities  
477 for precision medicine approaches in patients with advanced cancer, demonstrating the clinical  
478 utility of both germline PGx and DDI management strategies. Given their established clinical  
479 benefits and the abundant opportunities for their use demonstrated by our results, precision  
480 medicine approaches are likely to improve medication outcomes in cancer patients and may  
481 provide clinical benefit if incorporated into the workflow of molecular tumor boards. In order to  
482 facilitate widespread adoption of precision medicine approaches in this high-value patient  
483 population, future research is needed to (1) prospectively demonstrate the clinical benefit of

484 precision medicine approaches on patient outcomes and to (2) identify effective strategies for  
485 clinical implementation of precision medicine approaches.

486

487 **ACKNOWLEDGEMENTS**

488 None

489 **REFERENCES**

- 490 1. Claassens DMF, Vos GJA, Bergmeijer TO, et al: A Genotype-Guided Strategy for Oral  
491 P2Y<sub>12</sub> Inhibitors in Primary PCI. *N Engl J Med* 381:1621-1631, 2019
- 492 2. Mallal S, Phillips E, Carosi G, et al: HLA-B\*5701 screening for hypersensitivity to abacavir.  
493 *N Engl J Med* 358:568-79, 2008
- 494 3. Pirmohamed M, Burnside G, Eriksson N, et al: A randomized trial of genotype-guided  
495 dosing of warfarin. *N Engl J Med* 369:2294-303, 2013
- 496 4. U.S. Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug  
497 Labeling, (ed 08/18/20), 2020
- 498 5. Clinical Pharmacogenetics Implementation Consortium: Guidelines, 2020
- 499 6. Shugg T, Pasternak AL, London B, et al: Prevalence and types of inconsistencies in clinical  
500 pharmacogenetic recommendations among major U.S. sources. *NPJ Genom Med* 5:48, 2020
- 501 7. Bates DW, Cullen DJ, Laird N, et al: Incidence of adverse drug events and potential adverse  
502 drug events. Implications for prevention. ADE Prevention Study Group. *Jama* 274:29-34,  
503 1995
- 504 8. Wright A, Feblowitz J, Phansalkar S, et al: Preventability of adverse drug events involving  
505 multiple drugs using publicly available clinical decision support tools. *Am J Health Syst*  
506 *Pharm* 69:221-7, 2012
- 507 9. Arnold RJG, Tang J, Schrecker J, et al: Impact of Definitive Drug-Drug Interaction Testing  
508 on Medication Management and Patient Care. *Drugs Real World Outcomes* 5:217-224, 2018
- 509 10. U.S. Food and Drug Administration: Clinical Drug Interaction Studies -- Cytochrome P450  
510 Enzyme- and Transporter-Mediated Drug Interactions: Guidance for Industry, (ed January  
511 2020), 2020
- 512 11. Department of Health and Human Services Office of AIDS Research Advisory Council:  
513 Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2018
- 514 12. Grundy SM, Stone NJ, Bailey AL, et al: 2018  
515 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline  
516 on the Management of Blood Cholesterol: A Report of the American College of  
517 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.  
518 *Circulation* 139:e1082-e1143, 2019
- 519 13. LeBlanc TW, McNeil MJ, Kamal AH, et al: Polypharmacy in patients with advanced cancer  
520 and the role of medication discontinuation. *Lancet Oncol* 16:e333-41, 2015
- 521 14. Guthrie B, Makubate B, Hernandez-Santiago V, et al: The rising tide of polypharmacy and  
522 drug-drug interactions: population database analysis 1995-2010. *BMC Med* 13:74, 2015
- 523 15. Sharma M, Vadhariya A, Chikermane S, et al: Clinical Outcomes Associated with Drug-  
524 Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based  
525 Literature Review. *Drugs Aging* 36:341-354, 2019
- 526 16. Kato S, Kim KH, Lim HJ, et al: Real-world data from a molecular tumor board demonstrates  
527 improved outcomes with a precision N-of-One strategy. *Nat Commun* 11:4965, 2020
- 528 17. Relling MV, Schwab M, Whirl-Carrillo M, et al: Clinical Pharmacogenetics Implementation  
529 Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes:  
530 2018 Update. *Clin Pharmacol Ther* 105:1095-1105, 2019
- 531 18. Amstutz U, Henricks LM, Offer SM, et al: Clinical Pharmacogenetics Implementation  
532 Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and  
533 Fluoropyrimidine Dosing: 2017 Update. *Clin Pharmacol Ther* 103:210-216, 2018

- 534 19. Hicks JK, Sangkuhl K, Swen JJ, et al: Clinical pharmacogenetics implementation consortium  
535 guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic  
536 antidepressants: 2016 update. *Clin Pharmacol Ther* 102:37-44, 2017
- 537 20. Crews KR, Gaedigk A, Dunnenberger HM, et al: Clinical Pharmacogenetics Implementation  
538 Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014  
539 update. *Clin Pharmacol Ther* 95:376-82, 2014
- 540 21. Hicks JK, Bishop JR, Sangkuhl K, et al: Clinical Pharmacogenetics Implementation  
541 Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of  
542 Selective Serotonin Reuptake Inhibitors. *Clin Pharmacol Ther* 98:127-34, 2015
- 543 22. Hoffman JM, Haidar CE, Wilkinson MR, et al: PG4KDS: a model for the clinical  
544 implementation of pre-emptive pharmacogenetics. *Am J Med Genet C Semin Med Genet*  
545 166c:45-55, 2014
- 546 23. van der Lee M, Allard WG, Bollen S, et al: Repurposing of Diagnostic Whole Exome  
547 Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. *Clin Pharmacol Ther*  
548 107:617-627, 2020
- 549 24. Numanagić I, Malikić S, Ford M, et al: Allelic decomposition and exact genotyping of highly  
550 polymorphic and structurally variant genes. *Nat Commun* 9:828, 2018
- 551 25. U.S. Food and Drug Administration: Drug Development and Drug Interactions: Table of  
552 Substrates, Inhibitors and Inducers, (ed 03/10/20), 2020
- 553 26. Indiana University School of Medicine: Drug Interactions Flockhart Table, 2020
- 554 27. Lossignol D: A little help from steroids in oncology. *J Transl Int Med* 4:52-54, 2016
- 555 28. Chen YM, Lai CH, Chang HC, et al: Antacid Use and De Novo Brain Metastases in Patients  
556 with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were  
557 Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine  
558 Kinase Inhibitors. *PLoS One* 11:e0149722, 2016
- 559 29. Chu MP, Ghosh S, Chambers CR, et al: Gastric Acid suppression is associated with  
560 decreased erlotinib efficacy in non-small-cell lung cancer. *Clin Lung Cancer* 16:33-9, 2015
- 561 30. Ha VH, Ngo M, Chu MP, et al: Does gastric acid suppression affect sunitinib efficacy in  
562 patients with advanced or metastatic renal cell cancer? *J Oncol Pharm Pract* 21:194-200,  
563 2015
- 564 31. Mir O, Touati N, Lia M, et al: Impact of Concomitant Administration of Gastric Acid-  
565 Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated  
566 within the EORTC 62043/62072 Trials. *Clin Cancer Res* 25:1479-1485, 2019
- 567 32. Nichols D, Arnold S, Weiss HL, et al: Pharmacogenomic potential in advanced cancer  
568 patients. *Am J Health Syst Pharm* 76:415-423, 2019
- 569 33. Hertz DL, Glatz A, Pasternak AL, et al: Integration of Germline Pharmacogenetics Into a  
570 Tumor Sequencing Program. *JCO Precis Oncol* 2, 2018
- 571 34. Kasi PM, Koep T, Schnettler E, et al: Feasibility of Integrating Panel-Based  
572 Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With  
573 Colorectal Cancer. *Technol Cancer Res Treat* 18:1533033819873924, 2019
- 574 35. Zhou Y, Ingelman-Sundberg M, Lauschke VM: Worldwide Distribution of Cytochrome  
575 P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. *Clin Pharmacol*  
576 *Ther* 102:688-700, 2017
- 577 36. Riechelmann RP, Del Giglio A: Drug interactions in oncology: how common are they? *Ann*  
578 *Oncol* 20:1907-12, 2009

- 579 37. Chen L, Cheung WY: Potential drug interactions in patients with a history of cancer. *Curr*  
580 *Oncol* 21:e212-20, 2014
- 581 38. Ismail M, Khan S, Khan F, et al: Prevalence and significance of potential drug-drug  
582 interactions among cancer patients receiving chemotherapy. *BMC Cancer* 20:335, 2020
- 583 39. Korucu FC, Senyigit E, Köstek O, et al: A retrospective study on potential drug interactions:  
584 A single center experience. *Journal of Oncological Sciences* 4:80-84, 2018
- 585 40. van Leeuwen RW, Brundel DH, Neef C, et al: Prevalence of potential drug-drug interactions  
586 in cancer patients treated with oral anticancer drugs. *Br J Cancer* 108:1071-8, 2013
- 587 41. van Leeuwen RW, Swart EL, Boven E, et al: Potential drug interactions in cancer therapy: a  
588 prevalence study using an advanced screening method. *Ann Oncol* 22:2334-41, 2011
- 589 42. Yu G, Zheng QS, Wang DX, et al: Drug interactions between tyrosine-kinase inhibitors and  
590 acid suppressive agents: more than meets the eye. *Lancet Oncol* 15:e469-70, 2014
- 591 43. Zarca K, Durand-Zaleski I, Loriot MA, et al: Modeling the Outcome of Systematic TPMT  
592 Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness  
593 Analysis. *Mol Diagn Ther* 23:429-438, 2019
- 594 44. Fragoulakis V, Roncato R, Fratte CD, et al: Estimating the Effectiveness of DPYD  
595 Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of  
596 Chemotherapy-Induced Toxicity. *Am J Hum Genet* 104:1158-1168, 2019
- 597 45. Weitzel KW, Smith DM, Elsey AR, et al: Implementation of Standardized Clinical Processes  
598 for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons  
599 Learned. *Clin Transl Sci* 11:175-181, 2018
- 600 46. Hertz DL, Sahai V: Including DPYD on Cancer Genetic Panels to Prevent Fatal  
601 Fluoropyrimidine Toxicity. *J Natl Compr Canc Netw* 18:372-374, 2020
- 602 47. Bell GC, Caudle KE, Whirl-Carrillo M, et al: Clinical Pharmacogenetics Implementation  
603 Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.  
604 *Clin Pharmacol Ther* 102:213-218, 2017
- 605 48. Agergaard K, Mau-Sørensen M, Stage TB, et al: Clopidogrel-Paclitaxel Drug-Drug  
606 Interaction: A Pharmacoepidemiologic Study. *Clin Pharmacol Ther* 102:547-553, 2017
- 607 49. Shah HR, Ledbetter L, Diasio R, et al: A retrospective study of coagulation abnormalities in  
608 patients receiving concomitant capecitabine and warfarin. *Clin Colorectal Cancer* 5:354-8,  
609 2006
- 610 50. Malki MA, Pearson ER: Drug-drug-gene interactions and adverse drug reactions.  
611 *Pharmacogenomics J* 20:355-366, 2020

612

613

614

615

616

617

618



619 **FIGURE LEGENDS**

620 Figure 1. Subject-level prevalence for composite precision medicine opportunities, including  
621 actionable PGx, management of serious CYP-mediated DDIs, and management of DDIs  
622 including acid reducers and TKIs.

623  
624 Figure 2. Subject-level prevalence of clinically actionable phenotypes for major CYP enzymes  
625 based on genotype and due to CYP inhibitor-mediated phenoconversion.

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642 **TABLES**

643 **Table 1. Demographic and clinical characteristics of study cohort with advanced cancer.**

<b>Variable</b>	<b>Value in Full Cohort (n=481)</b>
Age in years at first cancer diagnosis (median [IQR])	57.4 (16.6)
Sex_(Count [Percent])	
Female	256 (53.2%)
Male	225 (46.8%)
Race (Count [Percent])	
White	423 (87.9%)
Black	38 (7.9%)
Asian	8 (1.7%)
Other*	3 (0.4%)
Unknown	9 (1.9%)
Cancer type at first diagnosis (Count [Percent])	
Breast	61 (12.7%)
Pancreatic	52 (10.8%)
Colorectal	46 (9.6%)
Prostate	40 (8.3%)
Soft-tissue sarcoma	36 (7.5%)
Ovarian	26 (5.4%)
Non-small cell lung	23 (4.8%)
Renal	18 (3.7%)
Thymic	13 (2.7%)
Cholangiocarcinoma	12 (2.5%)
Head and neck	11 (2.3%)
Bladder	10 (2.1%)
Unknown primary	13 (2.7%)
Duration of follow-up in years <sup>+</sup> (median [IQR])	2.9 (4.9)

644 \*One individual who reported a race of “other” reported Hispanic ethnicity.

645 <sup>+</sup>Defined as the time elapsed between the date of first cancer diagnosis and date of most recent  
646 prescription

**Table 2. Distribution of genotype-predicted phenotypes within study cohort for major pharmacogenes.**

<b>Gene</b>	<b>Ultrarapid Metabolizer</b>	<b>Normal Metabolizer</b>	<b>Intermediate Metabolizer</b>	<b>Poor Metabolizer</b>	<b>Indeterminate</b>	<b>Actionable</b>
<i>CYP2B6</i>		248 (51.6%)	199 (41.4%)	34 (7.1%)		<b>233 (48.4%)</b>
<i>CYP2C19</i>	153 (31.8%)*	189 (39.3%)	124 (25.8%)	9 (1.9%)	6 (1.2%)	<b>286 (59.5%)</b>
<i>CYP2C9</i>		321 (66.7%)	146 (30.4%)	14 (2.9%)		<b>160 (33.3%)</b>
<i>CYP2D6</i>	9 (1.9%)	254 (52.8%)	182 (37.8%)	24 (5.0%)	12 (2.5%)	<b>215 (44.7%)</b>
<i>CYP3A4</i>		437 (90.9%)	41 (8.5%)	2 (0.4%)	1 (0.2%)	<b>43 (8.9%)<sup>‡</sup></b>
<i>CYP3A5</i>		17 (3.5%)	71 (14.8%)	391 (81.3%)	2 (0.4%)	<b>88 (18.3%)</b>
<i>CYP4F2</i>		265 (55.1%)	175 (36.4%)	41 (8.5%)		<b>216 (44.9%)</b>
<i>DPYD</i>		476 (99.0%)	5 (1.0%)	0 (0%)		<b>5 (1.0%)</b>
<i>G6PD</i> <sup>+</sup>		474 (98.5%)	4 (0.8%)	3 (0.6%)		<b>7 (1.5%)</b>
<i>IFNL3 (IL28B)</i> <sup>+</sup>		204 (42.4%)	220 (45.7%)	57 (11.9%)		<b>0 (0%)</b>
<i>SLCO1B1</i> <sup>+</sup>		333 (69.2%)	107 (22.2%)	11 (2.3%)	30 (6.2%)	<b>118 (24.5%)</b>
<i>TPMT</i>		440 (91.5%)	35 (7.3%)	0 (0%)	6 (1.2%)	<b>35 (7.3%)</b>
<i>VKORC1</i> <sup>+</sup>		229 (47.6%)	199 (41.4%)	53 (11.0%)		<b>252 (52.4%)</b>

\*For CYP2C19, count in ultrarapid metabolizer column includes counts of both ultrarapid metabolizers (n=20) and rapid metabolizers (n=133).

<sup>+</sup>For designated genes, “normal metabolizer,” “intermediate metabolizer,” and “poor metabolizer” designations refer to subjects who are non-carriers, heterozygous, and homozygous for CPIC-defined actionable variants, respectively.

<sup>‡</sup>While CPIC does not make *CYP3A4* genetic-guided recommendations for any drugs, we classify subjects with one or two copies of the *CYP3A4*\*22 loss-of-function allele as intermediate and poor metabolizers, respectively, and consider these phenotypes to be actionable since they are used at our institution to guide tacrolimus dosing in *CYP3A5* non-expressers.

**Table 3. Prevalence of PGx medications prescribed in subjects with clinically actionable genotype-predicted phenotypes based on CPIC recommendations.**

<b>Drug-Genes Pair</b>	<b># Prescribed Drug</b>	<b>% with Actionable PGx</b>
Ondansetron- <i>CYP2D6</i>	256	0.8%
Pantoprazole- <i>CYP2C19</i>	171	4.7%
Omeprazole- <i>CYP2C19</i>	99	2.0%
Ibuprofen- <i>CYP2C9</i>	93	5.4%
Tramadol- <i>CYP2D6</i>	81	6.2%
Capecitabine- <i>DPYD</i>	62	0%
5-Fluorouracil- <i>DPYD</i>	40	0%
Sertraline- <i>CYP2C19</i>	28	0%
Escitalopram- <i>CYP2C19</i>	25	12.0%
Lansoprazole- <i>CYP2C19</i>	24	4.2%
Warfarin- <i>CYP2C9/CYP4F2/VKORC1</i>	24	87.5%
Citalopram- <i>CYP2C19</i>	21	23.8%
Simvastatin- <i>SLCO1B1</i>	21	23.8%
Meloxicam- <i>CYP2C9</i>	16	12.5%
Celecoxib- <i>CYP2C9</i>	15	0%
Amitriptyline- <i>CYP2C19/CYP2D6</i>	12	58.3%
Nortriptyline- <i>CYP2D6</i>	9	11.1%
Dexlansoprazole- <i>CYP2C19</i>	8	12.5%
Clopidogrel- <i>CYP2C19</i>	7	42.9%
Codeine- <i>CYP2D6</i>	7	14.3%
Paroxetine- <i>CYP2D6</i>	6	16.7%
Tamoxifen- <i>CYP2D6</i>	6	33.3%
Doxepin- <i>CYP2C19/CYP2D6</i>	3	100%
Voriconazole- <i>CYP2C19</i>	3	66.7%
Rasburicase- <i>G6PD</i>	2	0%
Atomoxetine- <i>CYP2D6</i>	1	0%
Azathioprine- <i>TPMT</i>	1	0%
Imipramine- <i>CYP2C19/CYP2D6</i>	1	100%
Phenytoin- <i>CYP2C9</i>	1	0%
Ribavirin- <i>IFNL3</i>	1	0%
Tacrolimus- <i>CYP3A5</i>	1	0%
<b>Total</b>	<b>1045</b>	

The “number prescribed drug” indicates the number of subjects within our cohort that were prescribed the corresponding drug. The “percent with actionable PGx,” which was calculated at the subject-level, indicates the percent of subjects prescribed the corresponding drug that had genotypes for which current CPIC guidelines recommend actionable clinical management strategies.

**Table 4. Number and prevalence of unique DDIs (i.e., unique co-prescription of a relevant drug-drug pair in a unique subject) by enzyme involved in n=469 subjects prescribed  $\geq 1$  medication, including (left) and excluding (right) DDIs involving corticosteroids.**

Enzyme	DDIs Including Corticosteroids				DDIs Excluding Corticosteroids			
	Total DDIs	DDIs/Subject (Mean)	DDI Prevalence (%)	Serious DDI Prevalence (%)	Total DDIs	DDIs/Subject (Mean)	DDI Prevalence (%)	Serious DDI Prevalence (%)
CYP2B6	1	0.00	0.2%	0.2%	1	0.00	0.2%	0.2%
CYP2C19	237	0.51	23.9%	11.7%	89	0.19	10.2%	5.8%
CYP2C8	0	0	0%	0%	0	0	0%	0%
CYP2C9	76	0.16	11.7%	4.7%	39	0.08	7.0%	2.3%
CYP2D6	695	1.48	45.2%	16.8%	695	1.48	45.2%	16.8%
CYP3A	392	0.84	29.9%	24.9%	217	0.46	20.3%	18.6%
<b>Any DDI</b>	<b>1401</b>	<b>2.99</b>	<b>50.3%</b>	<b>34.8%</b>	<b>1041</b>	<b>2.22</b>	<b>48.0%</b>	<b>29.4%</b>

**Note:** All DDI prevalence calculations are at the subject level.

## FIGURES

Figure 1.




Figure 2.

